Premium
Cannabidiol: An Overview of Some Pharmacological Aspects
Author(s) -
Mechoulam Raphael,
Parker Linda A.,
Gallily Ruth
Publication year - 2002
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.2002.tb05998.x
Subject(s) - cannabidiol , cannabinoid , pharmacology , cannabis , endocannabinoid system , cannabinoid receptor , antipsychotic , anandamide , mechanism of action , chemistry , tetrahydrocannabinol , mechanism (biology) , medicine , receptor , schizophrenia (object oriented programming) , psychiatry , biochemistry , philosophy , epistemology , in vitro , agonist
Over the past few years, considerable attention has focused on cannabidiol (CBD), a major nonpsychotropic constituent of cannabis. The authors present a review on the chemistry of CBD and discuss the anticonvulsive, antianxiety, antipsychotic, antinausea, and antirheumatoid arthritic properties of CBD. CBD does not bind to the known cannabinoid receptors, and its mechanism of action is yet unknown. It is possible that, in part at least, its effects are due to its recently discovered inhibition of anandamide uptake and hydrolysis and to its antioxidative effect.